Extracellular Vesicles as Carriers of Suicide mRNA and/or Protein in Cancer Therapy.
Methods Mol Biol
; 1895: 87-96, 2019.
Article
en En
| MEDLINE
| ID: mdl-30539531
ABSTRACT
Gene therapy involves the introduction of genes (termed transgenes) into cells to compensate for a deficiency or to make a beneficial protein. Gene therapy can used as a form of cancer treatment. A particularly attractive paradigm in this regard involves the selective introduction of transgenes into cancer cells that converts inactive prodrugs into active chemotherapeutic agents, thereby triggering the death of cancer cells. Since prodrugs are inactive, they tend not to cause significant side-effects and are well-tolerated by patients relative to conventional chemotherapy. Several viral and nonviral vectors have been used as delivery tools for suicide gene therapy. Extracellular vesicles (EVs) are now recognized as a promising class of nonviral delivery vectors. Here, we describe a method in which a suicide fusion gene construct is loaded into EVs derived from a non-tumorigenic cell line. Delivery of these modified EVs to glioblastoma cell lines and spheroids decreases glioblastoma cell viability, induces apoptotic cell death, and inhibits tumor growth in vivo.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Portadores de Fármacos
/
Terapia Genética
/
Glioblastoma
/
Genes Transgénicos Suicidas
/
Vesículas Extracelulares
Límite:
Humans
Idioma:
En
Revista:
Methods Mol Biol
Asunto de la revista:
BIOLOGIA MOLECULAR
Año:
2019
Tipo del documento:
Article
País de afiliación:
Finlandia